Key result
Early rhythm control improves AF outcomes while DOACs serve as primary thromboembolic therapy.
Why the study?
Evidence for the diagnosis and treatment of AF has expanded substantially since 2017.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Clinicians may consider early rhythm control and DOACs in AF; extends post-2017 evidence synthesis but leaves prospective validation open.
Evidence for diagnosis and treatment of atrial fibrillation (AF) has expanded substantially since 2017, when In the Clinic last considered this subject. Direct oral anticoagulants have become the predominant therapy for thromboembolic disease, and antidotes for these drugs are now available. Device-based left atrial appendage occlusion is frequently used in patients who cannot tolerate systemic anticoagulation, and growing evidence suggests that early rhythm control improves outcomes. Catheter ablation is now frequently performed to prevent recurrent AF. Managing risk factors for AF, such as hypertension, diabetes, and obesity, remains paramount in prevention of this condition.
No takes yet. Share an insight, caveat, or question.
Sana M. Al‐Khatib (2023) studied this question. Early rhythm control improves outcomes in patients with atrial fibrillation, while direct oral anticoagulants are now the primary therapy for thromboembolic disease.
Synapse has enriched 10 related papers. Consider them for comparative context: